Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1312266 | 0.99 | ALDH1A1 (0.45) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1314020 | 0.86 | MAPT (0.45) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1312291 | 0.86 | TMEM97 (0.45) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL1313239 | 0.84 | MAPT (0.44) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1315633 | 0.82 | SLC29A1 (0.42) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1314501 | 0.82 | MEN1 (0.59) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL1313452 | 0.81 | SLC29A1 (0.41) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL1313294 | 0.81 | MEN1 (0.58) | MAPTALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1312780 | 0.80 | FNTA (0.49) | MAPTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL1313380 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1KDM4ETMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | claimed |
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313096-A1 | NEW COMPOUNDS V | AstraZeneca AB (Publ) (SE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009147211-A1 | NEW COMPOUNDS V | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | MAPT 4483/4885ALDH1A1 1875/4885HPGD 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.